

SPECIAL ARTICLE

Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002

Viola Vaccarino, M.D., Ph.D., Saif S. Rathore, M.P.H., Nanette K. Wenger, M.D., Paul D. Frederick, M.P.H., M.B.A., Jerome L. Abramson, Ph.D., Hal V. Barron, M.D., Ajay Manhapra, M.D., Susmita Mallik, M.D., and Harlan M. Krumholz, M.D., for the National Registry of Myocardial Infarction Investigators

ABSTRACT

BACKGROUND

Although increased attention has been paid to sex and racial differences in the management of myocardial infarction, it is unknown whether these differences have narrowed over time.

METHODS

With the use of data from the National Registry of Myocardial Infarction, we examined sex and racial differences in the treatment of patients who were deemed to be “ideal candidates” for particular treatments and in deaths among 598,911 patients hospitalized with myocardial infarction between 1994 and 2002.

RESULTS

In the unadjusted analysis, sex and racial differences were observed for rates of reperfusion therapy (for white men, white women, black men, and black women: 86.5, 83.3, 80.4, and 77.8 percent, respectively; $P < 0.001$), use of aspirin (84.4, 78.7, 83.7, and 78.4 percent, respectively; $P < 0.001$), use of beta-blockers (66.6, 62.9, 67.8, and 64.5 percent; $P < 0.001$), and coronary angiography (69.1, 55.9, 64.0, and 55.0 percent; $P < 0.001$). After multivariable adjustment, racial and sex differences persisted for rates of reperfusion therapy (risk ratio for white women, black men, and black women: 0.97, 0.91, and 0.89, respectively, as compared with white men) and coronary angiography (relative risk, 0.91, 0.82, and 0.76) but were attenuated for the use of aspirin (risk ratio, 0.97, 0.98, and 0.94) and beta-blockers (risk ratio, 0.98, 1.00, and 0.96); all risks were unchanged over time. Adjusted in-hospital mortality was similar among white women (risk ratio, 1.05; 95 percent confidence interval, 1.03 to 1.07) and black men (risk ratio, 0.95; 95 percent confidence interval, 0.89 to 1.00), as compared with white men, but was higher among black women (risk ratio, 1.11; 95 percent confidence interval, 1.06 to 1.16) and was unchanged over time.

CONCLUSIONS

Rates of reperfusion therapy, coronary angiography, and in-hospital death after myocardial infarction, but not the use of aspirin and beta-blockers, vary according to race and sex, with no evidence that the differences have narrowed in recent years.

From the Department of Medicine, Division of Cardiology (V.V., N.K.W., J.L.A.) and Division of General Medicine (S.M.), Emory University School of Medicine; and the Department of Epidemiology, Rollins School of Public Health, Emory University (V.V.), Atlanta; the Section of Cardiovascular Medicine, Department of Medicine (S.S.R., H.M.K.), the Division of Health Policy and Administration, Department of Epidemiology and Public Health (H.M.K.), and the Robert Wood Johnson Clinical Scholars Program (H.M.K.) at Yale University School of Medicine and Yale–New Haven Hospital Center for Outcomes Research and Evaluation — both in New Haven, Conn.; the Ovation Research Group, Seattle (P.D.F.); Genentech, South San Francisco, Calif. (H.V.B.); and Hackley Hospital, Spring Lake, Mich. (A.M.). Address reprint requests to Dr. Vaccarino at the Department of Medicine, Division of Cardiology, Emory University School of Medicine, 1256 Briarcliff Rd., Suite 1N, Atlanta, GA 30306, or at viola.vaccarino@emory.edu.

N Engl J Med 2005;353:671-82.

Copyright © 2005 Massachusetts Medical Society.

IN RECENT YEARS, ATTENTION HAS BEEN focused on variations in the treatment of coronary heart disease that are related to the sex and race of the patient. Landmark studies in the late 1980s and early 1990s reported differences in treatment according to sex and race.¹⁻⁴ In the past decade, other investigations have described a generally consistent pattern of less intensive treatment of acute myocardial infarction in women, as compared with men,⁵⁻¹¹ and in blacks, as compared with whites,^{8,9,12-17} across a variety of settings. Efforts to remedy racial and sex differences in health care use have received prominent attention, including a recent Institute of Medicine report¹⁸ and the Public Health Service's Healthy People 2010 initiative.¹⁹

Although sex and racial differences in the treatment of coronary heart disease have been documented for more than a decade, little is known about whether these differences have persisted in more recent years. We assessed temporal trends in sex and racial differences in the use of guideline-based management for patients hospitalized with acute myocardial infarction.

METHODS

PATIENTS

Since July 1, 1990, hospitals participating in the National Registry of Myocardial Infarction (NRMI) have enrolled consecutive patients with myocardial infarction, as previously described.²⁰ Because NRMI-1 (July 1990 through May 1994) collected little information on patients' characteristics, we restricted our analysis to the 1,724,984 patients from 1917 hospitals who were enrolled in NRMI-2 (June 1994 through March 1998), NRMI-3 (April 1998 through June 2000), and NRMI-4 (July 2000 through May 2002). We excluded 12,132 patients with erroneous discharge dates and 381,018 patients who were transferred from another acute care hospital because their early treatments were not documented. We also excluded 131,474 patients who survived less than 24 hours because of insufficient time to begin treatments; 40,881 patients of unknown age, sex, race, or survival status; 60,689 patients whose race was not recorded as white or black; and 55,316 patients with missing data for model covariables. We restricted our analysis to 658 hospitals (out of 1917 hospitals) participating in NRMI for the full study period, resulting in a final sample of 598,911 patients. NRMI data collection

has previously been validated by comparison with the Cooperative Cardiovascular Project.²¹ This protocol was deemed exempt from review by the institutional review board at Emory University.

TREATMENT OF MYOCARDIAL INFARCTION

Patients were evaluated for the use of treatments recommended by the American College of Cardiology–American Heart Association (ACC–AHA) guidelines for the treatment of myocardial infarction since 1990.²²⁻²⁴ These included acute reperfusion therapy for patients with ST-segment elevation within 24 hours of admission, the administration of aspirin and beta-blockers within 24 hours of admission, and coronary angiography during hospitalization. As secondary treatment end points, we examined the frequency of coronary-artery bypass graft (CABG) surgery and percutaneous transluminal coronary angioplasty (PTCA) (except for primary PTCA, which was included in our definition of reperfusion therapy) during hospitalization.

To exclude racial or sex variations in treatment that may reflect differences in the proportion of patients for whom treatment is considered appropriate, we identified subgroups of patients who were ideally suited for each management strategy — in other words, patients with the strongest indications for treatment (ACC–AHA class I) and without major contraindications, according to guidelines published in 1990,²² 1996,²³ and 1999.²⁴ When variations were present in the three sets of guidelines, the 1996 guidelines were followed, since they are similar to the 1999 guidelines and were published closest to the beginning of our observation period.

To avoid bias in regard to the availability of services, rates of coronary angiography were calculated among patients admitted to facilities with full capability of performing invasive cardiovascular procedures. Rates of use of CABG and PTCA were calculated among patients admitted to these facilities who were “ideal candidates” for coronary angiography and who underwent angiography. Because information was lacking on angiographic findings, we were not able to define further patient eligibility for revascularization. The only contraindication to the use of aspirin in the initial management of myocardial infarction is true allergy to salicylates, which is uncommon and was not recorded in NRMI. Therefore, no ideal-candidate subgroup was created for aspirin.

IN-HOSPITAL MORTALITY

We examined trends in hospital mortality according to sex and race. This analysis was restricted to patients who were not transferred to another acute care hospital, since the survival status of transferred patients in the second hospital was unknown.

STATISTICAL ANALYSIS

We categorized patients into four groups according to race and sex: white men, white women, black men, and black women. Sex and racial differences in demographic and clinical factors and in the characteristics of hospitals were assessed over the full study period and stratified according to year of treatment (with a year defined as the period from June through May). We calculated crude rates of treatment and in-hospital mortality for the selected subgroups of ideal-candidate patients in the four groups.

We used logistic-regression models to derive the likelihood of treatment and death for the four groups.²⁵ We tested whether differences in the use of treatments according to sex and race changed over time by including a three-way interaction term reflecting the sex and race of patients and the year. Three consecutive models were constructed for each end point. Model 1 included sex, race, year, and all two-way and three-way interaction terms among sex, race, and year; model 2 expanded the data in model 1 to include other demographic and clinical factors; and model 3 expanded the data in model 2 to include characteristics of the hospitals. To assess whether the clustering of patients within hospitals affected our results, analyses were repeated with the use of generalized-estimating-equation models. The results were similar and are not reported. All analyses were performed using SAS software (version 8.2).

RESULTS

CHARACTERISTICS OF PATIENTS AND HOSPITALS

The mean age of patients did not change substantially over time, but the prevalence of most coronary risk factors increased in all subgroups (Table 1), whereas there was a decline in the proportion of patients with ST-segment elevation or Q waves on initial electrocardiography. The four subgroups showed similar time trends in most factors, as shown by the nonsignificant interaction among sex, race, and year. In all years combined, there were

substantial differences in many factors according to sex and race. For example, women in both racial groups were older than men, whereas blacks in both sex groups were younger than whites. As compared with white men, fewer female and black patients had ST-segment elevation or Q waves on initial electrocardiography, but women and blacks had more risk factors, a higher Killip class, and a longer delay to reach the hospital. As compared with whites, black patients tended to be hospitalized more often in facilities that were used for teaching, were affiliated with medical schools, were located in urban areas, and had equipment for performing cardiovascular procedures.

IDEAL CANDIDATES FOR TREATMENTS AND PROCEDURES

The proportion of patients qualifying as ideal candidates for reperfusion and the administration of beta-blockers was 50 percent or less and declined over time in all groups. At each time point, women and blacks were less likely than white men to be ideal candidates (Fig. 1). Approximately 10 percent of patients were classified as ideal candidates for coronary angiography. This percentage was similar in all sex and racial groups and fairly constant over time.

TREATMENTS AND PROCEDURES AMONG IDEAL CANDIDATES

In the unadjusted analysis, treatment rates differed according to sex and race, with rates highest in white men and lowest in black women (Table 2). Differences were larger for rates of reperfusion therapy and coronary angiography, particularly for black women, but smaller for the use of aspirin and beta-blockers. The use of aspirin and beta-blockers increased over time, whereas rates of reperfusion therapy remained stable and those of coronary angiography decreased slightly, with similar time trends in the four demographic groups. As a result, there was no significant variation over time in treatment differences according to sex or race.

Results that were adjusted for the characteristics of patients and hospitals were similar (Table 3). Because models 2 and 3 provided almost identical results, only the results of model 3 (adjusted for both patient and hospital characteristics) are presented. The interaction among the factors of sex, race, and year, as well as all other pairwise interactions, were not significant, indicating that racial and

Table 1. Demographic and Clinical Characteristics of Hospitalized Patients According to Sex, Race, and Study Year.*

Characteristic	White Men			White Women			Black Men			Black Women			P Value†									
	1994–1996 1998 2000 2002	1994–1996 1998 2000 2002	All Years†	1994–1996 1998 2000 2002	1994–1996 1998 2000 2002	All Years†	1994–1996 1998 2000 2002	1994–1996 1998 2000 2002	All Years†	1994–1996 1998 2000 2002	1994–1996 1998 2000 2002	All Years†										
Patients																						
Mean age (yr)	65.1	65.9	66.9	67.4	66.4	72.9	73.4	74.4	75.0	74.0	60.5	60.8	61.4	62.0	61.3	66.6	66.8	67.6	67.9	67.3	0.96	
Primary medical insurance (%)																						0.46
Age <65 yr and commercial insurer or PPO	24.2	21.7	21.8	21.0	22.1	10.9	9.8	9.7	9.5	9.9	21.0	18.1	19.2	18.2	19.0	13.1	10.6	10.5	11.0	11.2		
Age <65 and HMO	6.8	8.7	9.6	8.9	8.6	3.2	4.1	4.5	4.2	4.0	8.6	10.9	12.4	11.6	11.0	6.6	6.8	8.2	7.9	7.5		
Age <65 yr and Medicaid	1.5	1.4	1.3	1.4	1.4	2.0	1.8	1.7	1.7	1.8	4.7	4.3	4.3	5.0	4.6	7.1	6.9	6.4	5.9	6.5		
Age <65 yr and other type of insurance	10.8	9.5	7.0	6.7	8.4	5.5	4.8	3.4	3.1	4.1	17.7	17.8	14.1	13.1	15.5	10.1	10.7	8.3	7.0	8.8		
Medicare, age ≥65 yr	56.7	58.7	60.3	62.0	59.6	78.5	79.4	80.6	81.5	80.1	48.1	48.9	50.1	52.1	49.9	63.0	65.0	66.5	68.2	66.0		
Medical history (%)																						
Myocardial infarction	27.5	27.9	27.5	27.6	27.6	23.6	23.9	23.7	24.0	23.8	24.9	26.5	24.9	26.1	25.6	25.2	25.6	23.0	24.1	24.3	0.04	
Angina	18.5	17.7	14.0	12.5	15.5	19.9	18.8	14.1	12.4	15.9	14.2	13.9	11.5	9.2	12.0	16.8	16.6	12.0	9.5	13.2	0.25	
Heart failure	10.9	12.1	14.2	15.8	13.4	19.2	20.2	23.3	24.7	22.1	12.5	15.1	18.1	18.7	16.4	21.4	23.0	24.8	27.4	24.5	0.64	
PTCA	8.9	10.3	12.3	14.5	11.6	5.6	6.9	8.3	9.6	7.8	6.6	8.0	10.1	11.9	9.5	6.0	6.6	7.7	10.1	7.8	0.54	
CABG	14.6	15.8	17.5	18.8	16.8	8.2	9.5	10.2	10.9	9.8	6.6	7.7	9.1	10.2	8.5	5.8	6.4	7.3	8.4	7.2	0.63	
Stroke	7.1	8.0	9.3	9.2	8.5	9.8	10.6	12.6	12.4	11.5	9.5	10.2	12.5	12.3	11.3	12.2	14.1	15.4	14.8	14.3	0.17	
Diabetes	22.3	23.8	26.4	28.0	25.3	29.8	30.2	32.0	32.2	31.2	31.2	31.0	34.6	34.4	33.0	45.8	47.1	45.4	47.5	46.5	0.36	
Hypertension	44.6	47.6	51.3	55.3	49.9	56.5	59.8	63.5	66.8	62.1	62.9	65.9	68.1	70.8	67.3	74.3	77.0	78.5	81.5	78.3	0.61	
Current smoking	30.4	29.3	27.3	27.1	28.4	20.1	19.5	18.0	17.6	18.7	39.5	38.6	36.2	36.2	37.5	22.5	22.9	21.9	22.0	22.3	0.04	
Hypercholesterolemia	25.8	29.3	32.6	36.4	31.3	24.1	27.0	28.1	30.7	27.7	18.7	22.7	23.4	27.4	23.3	20.4	22.7	23.7	27.2	23.9	0.32	
Time from onset of symptoms to arrival at hospital																						
Mean (hr)	5.3	5.2	5.2	5.1	5.2	6.3	5.9	5.9	5.6	5.9	6.2	5.7	5.9	5.2	5.8	6.5	6.6	6.6	5.9	6.4	0.03	
Not available (%)	21.8	25.0	32.1	38.1	29.6	28.7	32.6	40.7	47.4	38.2	26.9	31.9	39.3	46.0	36.8	33.7	39.3	46.4	52.7	44.3	0.26	
Chest pain on presentation (%)	76.5	73.7	68.3	66.2	70.9	67.0	64.0	56.5	53.8	59.7	71.8	69.7	65.0	62.8	66.9	64.4	61.6	55.2	54.5	58.2	0.30	
Changes in first electrocardiogram (%)																						
ST-segment elevation	44.8	40.7	33.6	28.3	36.4	40.2	35.6	27.6	22.5	30.7	41.0	38.4	30.5	25.1	33.1	33.6	31.1	23.7	19.2	25.9	0.17	
ST-segment depression	28.3	29.4	28.4	27.3	28.3	28.3	29.1	27.6	25.8	27.6	24.6	25.5	23.3	21.8	23.7	23.6	24.7	23.1	20.8	22.9	0.34	
Q wave	12.0	10.2	8.7	7.8	9.6	10.8	9.0	7.0	6.5	8.1	9.7	9.1	7.3	6.4	8.0	7.9	7.9	5.4	5.6	6.5	0.32	
Left bundle-branch block	5.3	5.6	5.4	3.6	5.0	7.5	7.9	7.6	4.8	6.9	3.5	4.4	3.9	3.0	3.7	6.2	6.0	5.6	3.4	5.1	0.03	
Killip class (%)																						
1 (No heart failure)	78.9	78.6	78.1	78.1	78.4	67.9	68.3	68.0	68.6	68.2	75.9	76.2	74.2	75.2	75.3	67.1	66.5	68.1	67.6	67.4		
2 (Heart failure)	14.2	14.4	14.7	15.0	14.6	20.9	20.8	21.0	21.3	21.0	16.0	15.7	17.3	17.1	16.6	20.2	20.8	19.4	20.8	20.3		
3 (Pulmonary edema)	6.1	6.3	6.4	6.1	6.2	10.2	10.0	10.2	9.3	9.9	7.7	7.3	7.8	7.2	7.5	12.0	11.9	11.8	10.9	11.6		
4 (Cardiogenic shock)	0.8	0.7	0.8	0.8	0.8	1.0	0.9	0.7	0.8	0.8	0.5	0.7	0.7	0.6	0.6	0.7	0.9	0.7	0.7	0.8		


Mean systolic blood pressure (mm Hg)	144.9	145.1	144.3	143.7	144.5	145.5	146.3	145.6	145.1	145.6	149.9	148.4	147.7	147.6	148.3	150.5	150.9	151.1	151.2	151.0	0.008
Mean pulse (beats/min)	84.2	84.9	86.1	86.4	85.5	89.0	89.8	91.0	91.4	90.4	86.4	87.0	88.9	88.8	87.9	90.0	91.5	92.1	92.2	91.6	0.16
Creatine kinase or creatine kinase MB ≥ 2 times normal (%)	85.6	86.0	80.3	76.2	81.9	82.1	82.3	74.3	69.2	76.5	85.6	85.4	79.5	76.5	81.4	82.7	82.7	75.0	70.4	76.9	0.96
Ejection fraction (%)																					0.32
≥ 0.40	42.1	45.4	47.3	52.2	46.9	38.5	42.9	45.6	50.4	44.8	42.0	43.6	46.4	49.7	45.8	41.7	42.5	46.9	50.3	46.0	
< 0.40	15.3	17.5	19.4	22.4	18.8	14.7	16.8	18.4	21.6	18.2	17.4	19.9	23.9	26.4	22.3	16.1	19.0	20.0	23.9	20.2	
Not assessed	42.6	37.2	33.3	25.4	34.3	46.8	40.3	36.0	28.0	37.0	40.6	36.5	29.8	23.8	31.9	42.2	38.5	33.0	25.8	33.8	
Hospitals																					
Staffed beds > 200 (%)	72.9	72.7	73.1	73.7	73.1	71.7	72.4	71.8	72.3	72.1	84.4	85.2	86.5	86.6	85.8	85.6	85.4	86.9	86.8	86.3	0.47
Medical-school affiliation (%)	42.5	43.3	45.3	44.6	44.0	42.4	43.6	44.7	43.6	43.7	55.8	56.6	58.2	58.6	57.4	58.2	59.3	59.9	60.4	59.6	0.95
Teaching facility (%)	8.5	9.7	8.4	8.7	8.8	7.7	9.2	8.1	8.6	8.4	18.0	20.5	17.5	18.7	18.6	19.1	22.6	18.8	18.6	19.7	0.01
Urban location (%)	83.0	82.6	83.7	84.4	83.5	81.9	81.8	82.5	83.3	82.4	88.5	88.4	89.8	91.1	89.6	90.2	88.5	89.8	91.0	89.9	0.08
Facilities for cardiovascular procedures (%)																					0.31
None	17.1	15.7	13.8	11.7	14.5	19.0	17.1	15.5	13.8	16.1	9.8	7.9	8.7	7.9	8.5	8.8	7.1	7.9	7.4	7.7	
Coronary catheterization only	27.3	27.3	24.2	20.1	24.6	29.0	28.8	26.4	23.0	26.5	25.9	25.8	23.7	19.4	23.4	25.9	25.9	24.7	20.6	24.0	
PTCA, no open heart surgery	7.1	6.3	5.9	7.3	6.6	7.3	6.4	6.1	7.5	6.8	8.7	6.9	6.2	9.7	7.9	8.4	6.9	7.3	10.5	8.4	
PTCA and open heart surgery	48.5	50.7	56.1	60.8	54.3	44.7	47.7	52.0	55.6	50.5	55.5	59.4	61.4	63.0	60.2	57.0	60.0	60.1	61.4	59.9	
Quartile of myocardial-infarction volume (%)§																					0.15
≤ 79	5.5	4.8	4.0	3.4	4.4	6.0	4.9	4.5	3.9	4.7	3.0	3.0	2.8	2.4	2.8	3.5	2.8	3.6	2.5	3.1	
80–135	14.3	13.5	12.2	11.9	12.9	14.7	14.1	13.3	13.4	13.8	14.8	13.9	13.3	11.5	13.2	14.8	12.7	13.4	12.1	13.1	
136–228	26.6	25.1	24.8	24.4	25.2	28.1	26.3	25.6	26.0	26.4	32.1	29.4	29.6	28.9	29.9	30.3	31.4	31.7	30.8	31.1	
≥ 229	53.6	56.6	58.9	60.2	57.5	51.2	54.7	56.5	56.8	55.1	50.1	53.7	54.2	57.2	54.1	51.5	53.1	51.3	54.6	52.7	
Hospital ownership (%)																					0.77
Public	12.6	12.9	11.6	11.0	12.0	12.3	12.4	11.3	10.6	11.6	16.4	19.1	18.6	15.9	17.5	16.6	20.3	17.2	16.8	17.7	
Private, not-for-profit	82.5	81.9	82.7	83.5	82.7	83.3	83.0	83.6	84.5	83.6	79.7	75.2	76.7	79.8	77.9	79.3	75.3	78.3	79.6	78.2	
Private, for-profit	4.8	5.2	5.7	5.5	5.3	4.4	4.6	5.1	4.9	4.8	3.9	5.7	4.6	4.3	4.6	4.1	4.4	4.6	3.6	4.2	

* The study period was June to May, so there is overlap in years. HMO denotes health maintenance organization, PPO preferred provider organization, PTCA percutaneous transluminal coronary angioplasty, and CABG coronary-artery bypass grafting. Because of rounding, not all percentages total 100.

† $P < 0.01$ for the comparison of white men with white women, black men, and black women for all years combined, except for P values for creatinine kinase levels, which were two or more times the normal level among black men ($P = 0.33$).

‡ P values indicate whether there is a significant difference in the trend over time for factors among the four subgroups defined by sex and race.

§ Volume denotes the number of patients admitted with myocardial infarction per year.



sex differences in treatment did not change over time. In absolute terms, black women remained the group with the lowest rate of use of interventions. As compared with white men, the adjusted risk ratio for the use of reperfusion therapy in all years combined was 0.97 for white women, 0.91 for black men, and 0.89 for black women ($P < 0.001$ for all comparisons). For coronary angiography, corresponding estimates were 0.91, 0.82, and 0.76 ($P < 0.001$ for all comparisons). Adjusted differences for the use of aspirin and beta-blockers were small. For the use of aspirin, the risk ratio during the entire period was 0.97 for white women, 0.98 for black men, and 0.94 for black women, as compared with white men ($P < 0.001$ for all comparisons). For the use of beta-blockers, corresponding figures were 0.98 ($P < 0.001$), 1.00 ($P = 0.55$), and 0.96 ($P < 0.001$). Preferences of patients with respect to reperfusion therapy were recorded starting in 1998. These data show few refusals for reperfusion therapy (less than 0.5 percent) in each sex-and-race subgroup.

Analysis of secondary treatment end points indicated lower rates of use of CABG as compared with white men, with an adjusted risk ratio of treatment for white women, black men, and black women of 0.73, 0.74, and 0.63, respectively ($P < 0.001$ for all comparisons). Adjusted differences in rates of PTCA according to sex and race were small, except for black women (risk ratio, 0.89; 95 percent confidence interval, 0.83 to 0.95); white women had slightly higher rates of PTCA than did white men (risk ratio, 1.06; 95 percent confidence interval, 1.04 to 1.08). Data on the use of stents were available starting in 1998. There was a steady increase in stent use over time, from 73.1 percent in 1998 to 87.3 percent in 2000 through 2002. Similar proportions of patients undergoing PTCA received stents regardless of sex or race, with similar time trends. Racial and sex differences in the use of CABG and PTCA did not change over the study period.

MORTALITY

Overall, 21.7 percent of patients were transferred to other hospitals and excluded from assessment of in-hospital mortality. The proportion of patients who were transferred varied among groups according to race and sex: 23.2 percent for white men, 18.0 percent for white women, 18.3 percent for

Table 2. Unadjusted Rates of Treatments, Procedures, and Outcomes among Hospitalized Patients, According to Sex, Race, and Study Year.*

Characteristic	White Men			White Women			Black Men			Black Women										
	1994–1996	1996–2000	All Years	1994–1996	1996–2000	All Years	1994–1996	1996–2000	All Years	1994–1996	1996–2000	All Years								
Primary treatment end points	<i>percent</i>																			
Reperfusion therapy in first 24 hr for ideal candidates†	87.4	87.4	86.8	84.9	83.8	81.6	82.6	83.3	80.4	80.8	79.8	80.4	79.6	78.4	74.5	78.8	77.8			
Aspirin in first 24 hr, all patients	80.7	85.4	86.8	84.4	73.5	80.1	81.3	78.8	78.7	79.5	84.1	85.1	84.5	83.7	72.2	79.8	80.4	79.3	78.4	
Beta-blockers in first 24 hr for ideal candidates‡	54.7	63.2	69.3	79.7	66.6	49.7	59.7	65.6	62.9	57.1	62.9	71.2	80.0	67.8	49.8	60.7	69.1	75.6	64.5	
Coronary angiography for ideal candidates§	72.3	72.3	67.0	65.4	58.0	59.7	54.5	52.7	55.9	68.5	65.6	61.1	64.0	59.5	56.4	54.8	51.1	55.0		
Secondary treatment end points																				
CABG (excluding immediate CABG) for catheterized patients¶	25.5	26.6	26.4	28.1	26.7	22.4	22.3	23.1	22.8	19.5	21.6	20.5	22.7	21.1	15.9	18.2	23.7	20.4	19.8	
PTCA (excluding primary procedure) for catheterized patients¶	44.5	45.0	48.2	46.7	46.1	43.6	45.1	46.6	44.5	39.6	44.7	48.5	43.0	44.0	39.8	33.4	37.8	41.5	38.1	
In-hospital mortality for all patients	8.8	8.5	9.1	8.8	8.8	13.7	12.3	12.2	11.4	12.3	6.8	6.8	7.5	7.8	7.3	10.5	10.5	11.3	10.5	10.7

* The study period was June to May, so there is overlap in years. CABG denotes coronary-artery bypass grafting and PTCA percutaneous transluminal coronary angioplasty.

† Patients were considered ideal candidates for reperfusion therapy if they were less than 75 years of age, had ST-segment elevation on the first echocardiogram, presented within 12 hours after the onset of symptoms, did not have documented contraindications to fibrinolytic therapy (i.e., active internal bleeding or known bleeding diathesis; a history of stroke, recent surgery, or trauma; intracranial neoplasm; severe uncontrolled hypertension; or other documented contraindication), and did not decline to receive treatment.

‡ Patients were considered ideal candidates for beta-blocker therapy if they had a pulse of at least 60 beats per minute; did not have evidence of heart failure, shock, or hypotension (i.e., systolic blood pressure <100 mm Hg); and presented within 12 hours after the onset of symptoms.

§ Patients were considered ideal candidates for coronary angiography if they were admitted to hospitals fully able to perform invasive procedures and if they had had any of the following conditions: hypotension requiring intervention, recurrent angina, ischemia or infarction, cardiogenic shock, and hemodynamic instability.

¶ Patients were considered ideal candidates for coronary angiography and had undergone the procedure.

Secondary management end points																	
CABG (excluding immediate CABG) among catheterized patients																	
	0.88	0.84	0.88	0.83	0.85	0.76	0.81	0.78	0.81	0.79	0.62	0.68	0.90	0.73	0.74	0.89	0.42
Unadjusted																	
Adjusted¶	0.76	0.71	0.77	0.71	0.73	0.69	0.78	0.73	0.77	0.74	0.50	0.57	0.78	0.63	0.63	0.88	0.41
PTCA (excluding primary procedure) among catheterized patients																	
Unadjusted	0.98	1.00	0.97	0.95	0.98	0.89	0.99	1.01	0.92	0.95	0.89	0.74	0.78	0.89	0.83	0.08	0.52
Adjusted¶	1.06	1.10	1.04	1.04	1.06	0.92	0.99	1.02	0.92	0.97	0.98	0.79	0.81	0.94	0.89	0.049	0.48
In-hospital mortality for all patients																	
Unadjusted	1.52	1.42	1.33	1.29	1.38	0.77	0.81	0.82	0.88	0.82	1.19	1.23	1.24	1.19	1.21	0.80	0.72
Adjusted¶¶	1.10	1.10	1.01	0.99	1.05	0.92	0.94	0.92	0.99	0.95	1.03	1.11	1.14	1.11	1.11	0.73	0.31

* Patients were considered ideal candidates for reperfusion if they were less than 75 years of age, had ST-segment elevation on the first echocardiogram, presented within 12 hours after the onset of symptoms, did not have documented contraindications to fibrinolytic therapy (i.e., active internal bleeding or known bleeding diathesis; history of stroke, recent surgery, or trauma; intracranial neoplasm; severe uncontrolled hypertension; or other documented contraindication), and did not decline to receive treatment. The study period was June to May, so there is overlap in years. CABG denotes coronary-artery bypass grafting, and PTCA percutaneous transluminal coronary angioplasty.

† P values are for the interaction between sex and race.

‡ This P value indicates whether there is a significant difference in the trend over time for treatments or procedures among the four subgroups defined by race and sex.

§ P<0.01 for the comparison of white men with white women, black men, and black women, for all years combined, except for beta-blockers in black men (unadjusted P=0.05; adjusted P=0.55), PTCA in black men (unadjusted P=0.09; adjusted P=0.26), PTCA in white women (unadjusted P=0.02), and mortality in black men (adjusted P=0.06).

¶ Risk ratios were adjusted for age, insurance status, medical history (a history of myocardial infarction, angina, heart failure, stroke, diabetes, hypertension, or hypercholesterolemia; current smoking status; and previous CABG or PTCA), severity characteristics on admission (Killip class, systolic blood pressure, pulse, chest pain, left bundle-branch block, creatine kinase levels, location of anterior or septal infarct, and left ventricular ejection fraction [classified as <40 percent, ≥40 percent, or missing]), time from the onset of symptoms to hospital arrival (<3 hours, 3 to 6 hours, >6 to 12 hours, >12 hours, or not available), and hospital characteristics (number of beds; medical-school affiliation or teaching status; urban location; availability of invasive procedures, including catheterization, CABG, and PTCA; annual quartiles for the volume of myocardial infarction, and hospital ownership [including public, private not-for-profit, and private for-profit]).

¶¶ Risk ratios were adjusted for the same factors as those listed above, except that availability of invasive procedures was not included among hospital characteristics, since only patients admitted to hospitals fully able to perform invasive procedures were examined for the use of cardiovascular procedures.

tion,²⁸⁻³⁰ none examined such trends with respect to patients' sex or race. Studies of patients who were referred for cardiovascular evaluation^{31,32} found little difference in management according to sex, with little variation over time. One study that was based on administrative Medicare databases found smaller differences between blacks and whites in the use of coronary angiography and revascularization procedures in 1997 than in 1986.³³ Since results were adjusted only for sex and age, variations over time may reflect variations in the characteristics of patients or in their diagnoses, rather than in patterns of use in health care.

Despite considerable debate, reasons for these differences are largely unknown. Potential explanations are sex and racial differences in eligibility for treatment, clinical contraindications, and confounding by other clinical factors.³⁴ We mostly excluded these possibilities by focusing on ideal candidates and by adjusting for characteristics of patients and hospitals, although some misclassification is possible. It seems unlikely that misclassification affected our conclusions, because such errors should not have occurred differentially according to sex, race, or study year.

The preferences of patients regarding therapy may play some role in the treatment differences that were observed. Data on patients' preferences in NRMI were limited to reperfusion therapy in the latest years; therefore, we could not account for the preferences of patients in our analysis. However, available data indicated very low rates of refusal (less than 0.5 percent) in all sex and racial subgroups. Incomplete information regarding the time of the onset of symptoms could also contribute to differences in reperfusion therapy. These data were more often missing for white women, black men, and black women than they were for white men. To minimize potential bias, only patients with complete information regarding this factor were considered ideal candidates for reperfusion.

Probably, persistent differences in treatments and procedures according to sex and race reflect some unmeasured characteristic of patients or a health care factor that has not changed over time. There may be differences according to sex and race in the early presentation of myocardial infarction that lead to a delayed diagnosis in black women, white women, and black men. This may affect early treatment in these groups, particularly the use of reperfusion. Similarly, unmeasured health care fac-

tors may lead to inequalities in the delivery of care among demographic groups. A recent study found that black patients tend to be treated by primary care physicians with lower qualifications and to have less access to subspecialist care, diagnostic imaging, and nonemergency hospital admissions.³⁵ Although these results cannot be extrapolated to acute inpatient care, provider-level differences according to race may exist during an admission for myocardial infarction — for example, the likelihood or timing of referral to a specialist. Hospital-specific effects may also account for a large portion of racial and ethnic disparities in the time to reperfusion therapy,³⁶ suggesting important unmeasured hospital-level factors — perhaps poorer-quality centers treating a disproportionate number of minority-group patients. This, however, is not consistent with our observation of larger treatment disparities, in comparison with white men, for black women than for black men, two groups who presumably have similar rates of use of hospitals that serve members of racial minorities.

The lack of narrowing in some differences in treatment according to sex and race in recent years is a cause for concern. Differences in treatment paralleled to some extent differences in mortality in our study, since black women were also the group with the highest adjusted in-hospital mortality rate. A full understanding of the reasons underlying such differences requires further study.

Although clinical guidelines for the treatment of acute myocardial infarction changed somewhat during the study period, that change should not affect our results, since we focused on patients who, at each time point, were ideal candidates for each intervention and since the definition was the same for each sex and racial subgroup. We lacked information on whether a history of asthma, chronic obstructive pulmonary disease, dementia, or conduction disorders may have limited the use of beta-blockers or whether a history of hypersensitivity to salicylates or active ulcer disease may have discouraged the use of aspirin. There is no reason to expect that these contraindications differed according to sex or race over time. We also lacked data on socioeconomic factors, such as education and employment status, and were unable to separate the role of sex or race from these factors. Information regarding the time of the onset of symptoms was not available for all patients. The quantity of these missing data increased over time in all sex and racial sub-

groups with similar trends, making it unlikely that missing values introduced bias. Finally, we did not have access to angiographic data, so we cannot exclude the possibility that observed differences in rates of revascularization after coronary angiography reflected overuse of procedures in white men, rather than underuse in other groups of patients. For this reason, rates of revascularization procedures were considered secondary end points.

Differences in some treatments and procedures, particularly reperfusion therapy and coronary angiography, according to sex and race persist after

myocardial infarction, with no substantial changes from 1994 to 2002. Black women, the group with the lowest rate of use of interventions, have higher mortality rates than do other groups. Although the reasons for these differences are unknown, their persistence emphasizes the need for a continued search for explanations so that inequities in clinical care may be eliminated.

Supported in part by grants (K24HL077506, K12RR17643, and R01HS10407) from the National Institutes of Health and a training grant (GM07205) from the National Institute of General Medical Sciences. NRMI is supported by Genentech in South San Francisco, Calif.

REFERENCES

1. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. *N Engl J Med* 1991;325:221-5.
2. Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. *N Engl J Med* 1991;325:226-30.
3. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. *JAMA* 1989;261:253-7.
4. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. *N Engl J Med* 1993;329:621-7.
5. Yarzebski J, Col N, Pagley P, Savageau J, Gore J, Goldberg R. Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. *Am Heart J* 1996;131:43-50.
6. Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). *Am J Cardiol* 1996;78:9-14.
7. Gan SC, Beaver SK, Houck PM, MacLeshose RE, Lawson HW, Chan L. Treatment of acute myocardial infarction and 30-day mortality among women and men. *N Engl J Med* 2000;343:8-15.
8. Weitzman S, Cooper L, Chambless L, et al. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states. *Am J Cardiol* 1997;79:722-6.
9. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. *JAMA* 1996;275:1104-12.
10. Kostis JB, Wilson AC, O'Dowd K, et al. Sex differences in the management and long-term outcome of acute myocardial infarction. *Circulation* 1994;90:1715-30.
11. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. *Arch Intern Med* 1996;156:799-805. [Erratum, *Arch Intern Med* 1996;156:1920.]
12. Canto JG, Allison JJ, Kiefe CI, et al. Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. *N Engl J Med* 2000;342:1094-100.
13. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. *N Engl J Med* 1999;340:618-26. [Erratum, *N Engl J Med* 1999;340:1130.]
14. Chen J, Rathore SS, Radford MJ, Wang Y, Krumholz HM. Racial differences in the use of cardiac catheterization after acute myocardial infarction. *N Engl J Med* 2001;344:1443-9.
15. Epstein AM, Weissman JS, Schneider EC, Gatsonis C, Leape LL, Piana RN. Race and gender disparities in rates of cardiac revascularization: do they reflect appropriate use of procedures or problems in quality of care? *Med Care* 2003;41:1240-55.
16. Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. *JAMA* 1994;271:1175-80.
17. Hannan EL, van Ryn M, Burke J, et al. Access to coronary artery bypass surgery by race/ethnicity and gender among patients who are appropriate for surgery. *Med Care* 1999;37:68-77.
18. Smedley BD, Stith AY, Nelson AR, eds. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, D.C.: National Academy Press, 2003.
19. Department of Health and Human Services. Healthy People 2010: understanding and improving health. 2nd ed. Washington, D.C.: Government Printing Office, 2000.
20. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. *Circulation* 1994;90:2103-14.
21. Every NR, Frederick PD, Robinson M, Sugarman J, Bowlby L, Barron HV. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. *J Am Coll Cardiol* 1999;33:1886-94.
22. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). *J Am Coll Cardiol* 1990;16:249-92.
23. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *Circulation* 1996;94:2341-50.
24. Ryan TJ, Antman EM. 1999 Update: ACC/AHA guidelines for management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999;34:890-911.
25. Zhang J, Yu KE. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA* 1998;280:1690-1.
26. Arnold AL, Milner KA, Vaccarino V. Sex and race differences in electrocardiogram use (the National Hospital Ambulatory Medical Care Survey). *Am J Cardiol* 2001;88:1037-40.

27. Giles WH, Anda RF, Casper ML, Escobedo LG, Taylor HA. Race and sex differences in rates of invasive cardiac procedures in US hospitals: data from the National Hospital Discharge Survey. *Arch Intern Med* 1995;155:318-24.
28. Rogers WJ, Canto JC, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999. *J Am Coll Cardiol* 2000;36:2056-63.
29. Heidenreich PA, McClellan M. Trends in the treatment and outcomes for acute myocardial infarction: 1975-1995. *Am J Med* 2001;110:165-74.
30. Spencer F, Scleparis G, Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: a community-wide perspective. *Am Heart J* 2001;142:594-603.
31. Miller TD, Rogers VL, Hodge DO, Hopfenspirger MR, Bailey KR, Gibbons RJ. Gender differences and temporal trends in clinical characteristics, stress test results and use of invasive procedures in patients undergoing evaluation for coronary artery disease. *J Am Coll Cardiol* 2001;38:690-7.
32. Roeters van Lennep JE, Zwinderman AH, Roeters van Lennep HWO, et al. Gender differences in diagnosis and treatment of coronary artery disease from 1981 to 1997: no evidence for the Yentl syndrome. *Eur Heart J* 2000;21:911-8.
33. Escarce JJ, McGuire TG. Changes in racial differences in use of medical procedures and diagnostic tests among elderly persons: 1986-1997. *Am J Public Health* 2004;94:1795-9.
34. Rathore SS, Krumholz HM. Differences, disparities, and biases: clarifying racial variations in health care use. *Ann Intern Med* 2004;141:635-8.
35. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. *N Engl J Med* 2004;351:575-84.
36. Bradley EH, Herrin J, Wang Y, et al. Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. *JAMA* 2004;292:1563-72.

Copyright © 2005 Massachusetts Medical Society.

FULL TEXT OF ALL JOURNAL ARTICLES ON THE WORLD WIDE WEB

Access to the complete text of the *Journal* on the Internet is free to all subscribers. To use this Web site, subscribers should go to the *Journal's* home page (www.nejm.org) and register by entering their names and subscriber numbers as they appear on their mailing labels. After this one-time registration, subscribers can use their passwords to log on for electronic access to the entire *Journal* from any computer that is connected to the Internet. Features include a library of all issues since January 1993 and abstracts since January 1975, a full-text search capacity, and a personal archive for saving articles and search results of interest. All articles can be printed in a format that is virtually identical to that of the typeset pages. Beginning six months after publication, the full text of all Original Articles and Special Articles is available free to nonsubscribers who have completed a brief registration.